Protagonist Therapeutics (PTGX)
(Real Time Quote from BATS)
$25.03 USD
-0.19 (-0.75%)
Updated Apr 19, 2024 12:18 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
PTGX 25.03 -0.19(-0.75%)
Will PTGX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PTGX
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks to Buy for Attractive Earnings Acceleration
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Other News for PTGX
Protagonist Therapeutics Inc CEO Sells 25,000 Shares
Protagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic Partnerships
Protagonist expects to reach VERIFY enrollment target by end of March
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Catalyst Watch: Walgreens earnings, UPS analyst day and Xiaomi's luxury EV debut